X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

BCEL

Closed

Atreca Inc

0.09
0.00 (0.00%)
Last Update: 14 Jun 2024 22:28:00
Yesterday: 0.0912
Day's Range: 0.09 - 0.0931
Send
When Written:
 
1.14
Atreca Inc. is a biotechnology company based in Redwood City, California that focuses on developing novel therapeutics using its proprietary Immune Repertoire Capture (IRC™) technology. The IRC™ technology enables the identification and analysis of functional antibodies that are naturally produced by the human immune system in response to various diseases. Atreca's approach is to use these antibodies as a starting point to develop new therapies for a range of diseases, including cancer and autoimmune disorders.

Atreca was founded in 2010 by a team of scientists from Stanford University, including Dr. Tito Serafini, Dr. John Shively, and Dr. Guy Cavet. The company has raised over $400 million in funding from investors such as Wellington Management, Cormorant Asset Management, and EcoR1 Capital.

Atreca's pipeline includes several drug candidates in preclinical and clinical development, including ATRC-101, a monoclonal antibody targeting the immune checkpoint protein PD-1, which is currently in Phase 1 clinical trials for the treatment of solid tumors. The company also has partnerships with pharmaceutical companies such as Genentech and Bayer to develop new therapies using its IRC™ technology.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X